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Background: Many clinicians and hepatitis B virus (HBV)-infected pregnant women prefer elective caesarean
section (ECS) to prevent mother-to-child transmission of HBV, since some studies found higher transmission of HBV
in infants born by vaginal delivery (VD) than by cesarean section. However, other studies showed that ECS does not
reduce the risk of being infected with HBV in infants. In this study, we aimed to clarify whether ECS may reduce the
risk of mother-to-child transmission of HBV.
Methods: Totally 546 children (1–7-year-old) born to 544 HBsAg-positive mothers from 15 cities and rural areas
across Jiangsu Province, China, were enrolled. Of these children, 137 (2 pairs of twins) were born to HBeAg-positive
mothers; 285 were delivered by ECS and 261 others by VD (one pair of twin in each group). HBV serologic markers
were tested by enzyme or microparticle immunoassay.
Results: The maternal and gestational ages, maternal HBeAg-positive rates, and children’s ages, gender ratios,
hepatitis B vaccine coverage and administrations of HBIG were comparable between ECS and VD groups
(all p >0.05). The overall prevalence of HBsAg in the 546 children was 2.4%, with 2.5% (7/285) and 2.3% (6/261) in
those born by ECS and VD respectively (p = 0.904). Further comparison of chronic HBV infection in the 137 children
of HBeAg-positive mothers showed that the HBsAg-positive rates in ECS and VD groups were 10.3% (7/68) and
8.7% (6/69) respectively (p = 0.750), while the mothers had similar HBV DNA levels (2.38 × 106 vs. 2.35 × 106 IU/ml,
p = 0.586). Additionally, the overall rate of anti-HBs ≥10 mIU/ml in the children was 71.6%, with 72.3% and 70.9%
in those born by ECS and VD respectively (p = 0.717).
Conclusions: With the recommended immunoprophylaxis against hepatitis B, ECS does not reduce the risk of
mother-to-child transmission of HBV. Therefore, ECS should not be used in HBsAg-positive pregnant women to
prevent mother-to-child transmission of HBV.
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Hepatitis B virus (HBV) infection remains a major health
threat worldwide; each year over one million individuals
die from HBV-related diseases, including cirrhosis and
hepatocellular carcinoma. Mother-to-child transmission
of HBV has been recognized as the major cause of
chronic HBV infection, particularly in highly endemic
areas such as Southeast Asia and Africa [1]. Therefore,* Correspondence: yzh20061111@yahoo.com
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reproduction in any medium, provided the orprevention of mother-to-child transmission of HBV is
critical to control the infection. The recommended
immunoprophylaxis against hepatitis B, including use of
hepatitis B vaccine and hepatitis B immune globulin
(HBIG) in infants, has been proven to be the most ef-
fective way to reduce perinatal HBV transmission.
Mother-to-child transmission of HBV occurs mainly
during and soon after delivery, through direct contact of
the infant with infectious blood and other body fluids.
Previous studies demonstrated that elective cesarean
section (ECS) may reduce the risk of mother-to-child
transmission of some viruses, such as human immuno-
deficiency virus and herpes simplex virus [2,3]. Similarly,
some studies found that HBV infection rate in infantsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fants born by ECS [4-6]. Therefore, many clinicians and
HBV-infected pregnant women prefer ECS to prevent
mother-to-child transmission of HBV [7], although other
reports show that ECS does not reduce the likelihood of
HBV infection in infants [8,9]. In this study, we com-
pared the HBV infection rates in children of hepatitis B
surface antigen (HBsAg)-positive mothers who delivered
their babies by ECS or VD to clarify the issue of whether
ECS may reduce the risk of mother-to-child transmis-
sion of HBV.
Methods
Subjects and serum specimens
In the present study, two groups of children born to
HBsAg-positive mothers were recruited. The first group
was composed of 296 singleton full-term children and
their 296 HBV-infected mothers. These mothers were
selected based on the results of a retrospective study on
the prevalence of HBsAg among pregnant women from
14 cities and rural areas across Jiangsu during 2002–
2004 [10]; they were all HBsAg-positive during their
pregnancy and at delivery. Serum samples (~3 ml each)
from these 296 children were prospectively collected
from October 2009 to March 2010, when they were at
5–7 years old. The second group was comprised of 250
children aged 1–6 years who were born to 248 HBV-
infected mothers (2 pairs of twins). These children were
recruited based on our invitation of 385 mothers, who
were all HBsAg-positive during their pregnancy and de-
livered their babies in Zhenjiang Fourth People's Hos-
pital, Jiangsu, from January 2006 to December 2010, to
join this study. Blood sample (~3 ml each) was collected
from each child from November 2011 to March 2012.
Each attending mother was asked to complete a ques-
tionnaire, which included demographic data of the
mother and her child, the use of HBIG and first dose
hepatitis B vaccine in the children. These data were all
further validated by checking the hospital records. In
addition, the results of HBV serologic markers and HBV
DNA levels in each mother at delivery were retrieved
from medical records. The use of second and third doses
of hepatitis B vaccine was confirmed in 90.3% of the
children by checking the children's vaccination records,
and that in other instances was defined by the interview
with children’s mothers.
All mothers had no coinfection with hepatitis C virus
and human immunodeficiency virus, and had not re-
ceived amniocentesis or anti-viral treatment before and/
or during pregnancy. Those with maternal complications,
such as acute hepatitis and threatening abortion, were
also excluded. Totally 546 children (2 pairs of twins)
born to 544 HBsAg-positive mothers were enrolled. The
mothers were 23–48 years of age (mean, 31.0 ± 3.5), andthe gestational ages were 35–42 weeks (39.5 ± 1.0). The
children (296 boys) were 1–7 years old (4.7 ± 1.7) during
follow-up; 25.1% (137/546) were born to hepatitis B e
antigen (HBeAg)-positive mothers.
This study was performed according to the Declaration
of Helsinki and approved by the institutional review
boards of Nanjing Drum Tower Hospital and Zhenjiang
Fourth People's Hospital. Each mother gave the written
informed consent for the use of her child’s blood samples.
Assays for HBV serologic markers
Commercial enzyme immunoassay kits (Huakang Biotech,
Shenzhen; Kehua Bio-Engineering, Shanghai, China) were
used for qualitative testing of HBV serologic markers, in-
cluding HBsAg, antibody against hepatitis B surface anti-
gen (anti-HBs), and antibody against hepatitis B core
antigen (anti-HBc). All HBsAg-positive specimens were
also tested for HBeAg and antibody against hepatitis B e
antigen (anti-HBe) by EIA (Huakang Biotech; Kehua Bio-
Engineering). Quantitative analysis of anti-HBs in a serum
sample was further performed using a microparticle im-
munoassay kit (Architect system, Abbott, North Chicago).
Positive and negative controls were included in each test.
All samples were tested by two technicians who were un-
aware of the serum identity. When anti-HBs was beyond
the upper detection limit (1000 mIU/ml), the specimens
were retested after further dilution with 20% bovine fetal
serum in phosphate-buffer saline.
Statistical analysis
Data analysis was performed using SPSS software version
17.0 (SPSS Standard version 17.0, SPSS Inc., Chicago, IL).
Continuous variables normally distributed were expressed
as mean ± standard deviation (SD) and compared by t-test
between two groups. Quantitative data non-normally dis-
tributed were presented as median and interquartile range.
Categorical variables were reported as number and per-
centage and compared by χ2 test or Fisher’s exact test
where appropriate. A two-sided p value of <0.05 was con-
sidered as statistically significant.
Results
General characteristics of the study population
Of the total 546 children, 285 (52.2%) were delivered by
ECS and 261 others (47.8%) were delivered by VD. They
were born to 284 and 260 mothers respectively, one pair
of twin in each group. The mothers of the children in the
two groups had comparable maternal and gestational ages
and HBeAg-positive rates (Table 1). The children in the
ECS and VD groups also had similar ages, gender ratios,
feeding modes, hepatitis B vaccine coverage and adminis-
trations of HBIG (Table 1). All the children were generally
in good health at the follow-up.
Table 1 General characteristics of children and their






Maternal age, mean (SD) 31.3 ± 3.7 30.8 ± 3.4 0.093
Gestational age, mean (SD) 39.3 ± 0.9 39.6 ± 1.1 0.892
Mother with positive HBeAg, n (%) 67 (23.6) 68 (26.2) 0.489
Child’s age, mean (SD) 4.6 ± 1.8 4.8 ± 1.7 0.106
Male child, n (%) 152 (53.3) 144 (55.2) 0.667
Breast/formula-feeding 202/83 195/66 0.315
Timely first dose vaccine, n (%) 259 (90.9) 230 (88.1) 0.293
Hepatitis B vaccine coverage, n (%) 285 (100) 261 (100) ND
HBIG within 24 hours after birth, n (%) 162 (56.8) 129 (49.4) 0.083
a There was one pair of twin born to HBeAg-positive mother in each group.
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HBV infection was defined by the positive results of
HBsAg, anti-HBc, and HBeAg. The overall rate of chronic
HBV infection in the children of HBsAg-positive mothers
was 2.4% (13/546), although they were all vaccinated
against hepatitis B and mostly administered with HBIG
within 24 hours after birth. As shown in Table 2, the rate
of chronic infection and self-resolved infection, presented
as HBsAg-negative and anti-HBc-positive, in the VD
group was 2.3% (6/261) and 3.8% (10/261) respectively,
each comparable to that in the ECS group (p = 0.904 and
0.355 respectively).
It has been demonstrated that the major risk factor re-
sponsible for mother-to-child transmission of HBV is the
viral load in mothers [11]. Maternal HBeAg positivity is
well correlated with the HBV DNA levels [12]. Thus, in-
fants of HBeAg-positive mothers have an increased risk of
becoming infected with HBV. In agreement with the find-
ings, all 13 infected children in the present study were
born to HBeAg-positive mothers and none of the children
born to HBeAg-negative mothers was chronically infected.
To clarify whether ECS may reduce the likelihood of
mother-to-child transmission of HBV in these high-risk
children, we compared the incidence of HBV infection in
68 children of HBeAg-positive mothers who underwent
ECS with that in 69 other children of HBeAg-positive
mothers who delivered vaginally. The mothers who deliv-
ered their babies by ECS had comparable HBV DNA
levels with those who delivered their babies by VD (2.38 ×Table 2 HBV serologic markers in 546 children of
HBsAg-positive mothers who delivered their infants
by ECS and VD
Serologic marker ECS (n = 285) VD (n = 261) p
HBsAg+, n (%) 7 (2.5) 6 (2.3) 0.904
Anti-HBc+/HBsAg–, n (%) 7 (2.5) 10 (3.8) 0.355
Anti-HBs ≥10 mIU/ml, n (%) 206 (72.3) 185 (70.9) 0.717106 vs. 2.35 × 106 IU/ml, p = 0.586). Similarly, as shown in
Table 3, the rates of chronic infection and self-resolved in-
fection were both comparable between the two groups
(10.3% vs. 8.7%, p = 0.750 and 5.9% vs. 13.0%, p = 0.153).
Anti-HBs levels in children
Of the 546 children who had been vaccinated against
hepatitis B, 391 (71.6%) had anti-HBs ≥10 mIU/ml, which
is similar to the findings in children with same ages [13].
The anti-HBs positive (≥10 mIU/ml) rate in the 291 chil-
dren who were administered HBIG at birth was not differ-
ent from that in those who were not administered HBIG
(74.9% vs. 67.8%, p = 0.068). Furthermore, the positive rate
of anti-HBs in children born by ECS was similar to that in
children born by VD, even in those born to HBeAg-
positive mothers (Tables 2 and 3).
Discussion
Our study showed that, under the currently available
immunoprophylaxis against hepatitis B, children of HBs
Ag-positive mothers delivered by ECS and VD had a simi-
lar prevalence of HBsAg, demonstrating that ECS does
not reduce the risk of mother-to-child transmission of
HBV. Therefore, ECS should not be used as a measure to
prevent mother-to-child transmission of HBV.
Although HBV DNA may be detected in maternal blood
and other body fluids of HBV carrier mothers and ECS
may shorten the time of delivery [14], we found in the
present study that the HBV infection rate in the children
delivered by ECS was comparable with that in the other
children delivered by VD (Table 2). Since the percentage
of HBeAg-positive mothers, the use of hepatitis B vaccine
and HBIG in children and other general characteristics
were comparable between the ECS and VD groups
(Table 1), the infection rate in either group was not
influenced by these factors. Additionally, the HBeAg-
positive rate (24.8%) in HBV-infected pregnant women in
the present study was in accordance with the rates
reported in previous studies [15,16], suggesting that the
study subjects were representative. Since infants of
HBeAg-positive mothers are more prone to be infected
[17], we further analyzed the HBV infection in the 137
children of HBeAg-positive mothers. The results demon-
strated that ECS does not reduce the risk of mother-Table 3 HBV serologic markers in 137 children of
HBeAg-positive mothers who delivered their babies
by ECS and VDa
Serologic marker ECS (n = 68) VD (n = 69) p
HBsAg+, n (%) 7 (10.3) 6 (8.7) 0.750
Anti-HBc+/HBsAg–, n (%) 4 (5.9) 9 (13.0) 0.153
Anti-HBs ≥10 mIU/ml, n (%) 55 (80.9) 52 (75.4) 0.408
a The mothers in ECS and VD groups had comparable HBV DNA levels (2.38 ×
106 vs. 2.35 × 106 IU/ml, p = 0.586).
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Before the availability of HBIG and hepatitis B vaccine,
Chen et al. [8] described a cohort of 23 infants born by
ECS and 73 infants born by VD, whose mothers were all
asymptomatic chronic HBV carriers; the mother-to-child
transmission was similar in infants (≥ 6 months) deliv-
ered by ECS and VD (39.1% vs. 43.8%). In addition, the
rates of acquisition of HBsAg were comparable between
the infants born after the first stage of labor >9 hours
and ≤9 hours (41.9% vs. 45.2%). The data show that
prolonged labor and uterine contractions at delivery play
little role in mother-to-child transmission of HBV. Wang
et al. [9] also indicated no significant effects of delivery
mode on the prevention of mother-to-child transmission
of HBV. Recently, using highly sensitive real-time PCR,
Papaevangelou et al. [18] reported that HBV DNA in per-
ipheral blood of newborns was more often detected than
HBsAg, however, no difference in the incidence of neo-
natal viremia was observed between the babies born by
ECS and VD (21.9% vs. 26.5%, p = 0.685). Our data in the
present study are in accordance with these reported
results.
Lee et al. [4] advised ECS for HBeAg-positive pregnant
women because they found higher rate of HBV infection
in infants delivered vaginally within 6 months of age and
serum HBV DNA at birth. Similarly, a recent study in
India presented higher transmission of HBV in babies de-
livered by vaginal route than by cesarean section [5].
However, these two studies did not follow the infants to
9–18 months old, the age point by which the perinatal
infection can be defined [19]. Furthermore, although a
systematic review suggested that ECS appears to be ef-
fective in preventing mother-to-child transmission of
HBV [6], high risk of bias included in the analyses should
not be overlooked.
It is concerning to see that the birth dose vaccine was
delayed in 10.4% of the newborns and only half of the in-
fants in the present investigation received HBIG within
24 hours after birth. The untimely use of first dose vaccine
and the low rate of HBIG administration indicated that
there are considerable gaps in the immunoprophylaxis
against hepatitis B between the national recommendations
and routine practices in China [20]. Therefore, more mea-
sures should be taken in the future to achieve full adher-
ence to the recommended prophylaxis in preventing
mother-to-child transmission of HBV.
The main limitation in our study is that the mothers’ de-
livery modes were not randomly assigned. However, as
mentioned above, maternal and neonatal general charac-
teristics were comparable between ECS and VD groups.
Furthermore, maternal HBeAg-positive rates and HBV
DNA levels in HBeAg-positive mothers were also similar
between the two groups. Thus, it was less likely the non-randomized design in the present study may result in sig-
nificant bias. Additionally, ethical considerations will not
allow such a randomized study. The other minor flaw is
that the use of second and third doses of hepatitis B vac-
cine in some 10% of the children was defined by the inter-
view with their mothers. However, we consider that the
data were reliable because all newborns in China have re-
ceived three doses of hepatitis B vaccine without charge
since 2002 [21]. Additionally, the overall HBsAg-positive
rate (2.4%, 13/546) and the rate (71.6%) of anti-HBs ≥10
mIU/ml also indicate that these children had been vacci-
nated against hepatitis B.
Conclusion
In conclusion, with passive and active immunoprophylaxis
against hepatitis B, ECS does not reduce the risk of
mother-to-child transmission of HBV in infants of HBV
carrier mothers. Therefore, ECS should not be recom-
mended in HBsAg-positive pregnant women to prevent
mother-to-child transmission of HBV.
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